TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01870284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study: NCT03765801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRTA9906 60 mg PR tablet
Description: GRTA9906 60 mg PR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRTA9906 60 mg PR tablet
Description: GRTA9906 60 mg PR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRTA9906 60 mg IR capsule
Description: GRTA9906 60 mg IR capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRTA9906 60 mg IR capsule
Description: GRTA9906 60 mg IR capsule
Study: NCT03107611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus Cream, 1%
Study: NCT03221322

Intervention type: BEHAVIORAL
Intervention: Superlean
Description: Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.

Intervention type: BEHAVIORAL
Intervention: Superlean
Description: Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
Study: NCT01186146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin monotherapy
Description: stopping clopidogrel at 1 year after DES
Study: NCT01870284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT01186146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin,Clopidogrel
Description: continue aspirin and clopidogrel 1year after DES
Study: NCT00686517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b
Description: 1.5 ug/kg/week SC for 12 or 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b
Description: 1.5 ug/kg/week SC for 12 or 24 weeks
Study: NCT01870284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC
Study: NCT04321070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate
Description: A thin film of investigation product will be applied to the affected areas of the face once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin Phosphate RLD
Description: A thin film of investigation product will be applied to the affected areas of the face once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: A thin film of investigation product will be applied to the affected areas of the face once daily
Study: NCT02004522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: PI3K Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: monoclonal antibody
Study: NCT01787331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02566486

Intervention type: DEVICE
Group type: OTHER
Intervention: Reciprocating system
Description: Different root canal instrumentation systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Rotational system
Description: Different root canal instrumentation systems
Study: NCT03831789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar targeted rTMS
Description: 10 Hz cerebellar rTMS (250 pulses)
Study: NCT02796651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (6 μg)
Description: Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol furmarate (20 μg)
Description: Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
Study: NCT03831789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar targeted rTMS
Description: 10 Hz cerebellar rTMS (250 pulses)
Study: NCT03483025

Intervention type: OTHER
Group type: OTHER
Intervention: Skin Testing of Hair cleansing products
Description: 6 different commercially available shampoos

Intervention type: OTHER
Group type: OTHER
Intervention: Skin Testing of Hair cleansing products
Description: 6 different commercially available shampoos

Intervention type: OTHER
Group type: OTHER
Intervention: Skin Testing of Hair cleansing products
Description: 6 different commercially available shampoos

Intervention type: OTHER
Group type: OTHER
Intervention: Skin Testing of Hair cleansing products
Description: 6 different commercially available shampoos

Intervention type: OTHER
Group type: OTHER
Intervention: Skin Testing of Hair cleansing products
Description: 6 different commercially available shampoos

Intervention type: OTHER
Group type: OTHER
Intervention: Skin Testing of Hair cleansing products
Description: 6 different commercially available shampoos
Study: NCT01072422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation
Description: Use of trying to quit smoking instrument and quit smoking advice
Study: NCT00911547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: 10 mg tablet taken once daily at bedtime for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: 10 mg tablet taken once daily at bedtime for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone
Description: 200 ug inhaled, taken twice daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone
Description: 200 ug inhaled, taken twice daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhaler
Description: placebo inhaler taken twice daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhaler
Description: placebo inhaler taken twice daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo tablet
Description: placebo tablet taken once daily at bedtime for 16 weeks
Study: NCT00686517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b
Description: 1.5 ug/kg/week SC for 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
Study: NCT01550718

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ESML-EX (Physical Activity Program)
Description: ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ESML-Social (Social Activity Program)
Description: ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session.
Study: NCT04437017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine+NK-1 RA+5-HT3 RA
Description: On day 1-4, Olanzapine (5mg) is delivered orally after dinner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone+NK-1 RA+5-HT3 RA
Description: On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.
Study: NCT03635112

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-1473
Description: TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-1473
Description: TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TD-1473
Description: TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
Study: NCT02853474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Palliative Care visit
Description: A PC visit is a visit done by a PC physician. Any kind of visits done by other professionals IS NOT a PC visit.~Five PC visits are scheduled in this arm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: EORTC-QLQ-C30 questionnaire
Description: The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EORTC-QLQ-C30 questionnaire
Description: The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: HADS score
Description: The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HADS score
Description: The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.
Study: NCT03136081

Intervention type: DIAGNOSTIC_TEST
Intervention: Candidiasis infection occurence
Description: Candidiasis infection occurence
Study: NCT05445622

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: learning spinal mobilization with a force sensor
Description: Experimental group will use a force sensor (Active5) while learning spinal mobilization during the practice lab portion of the class. The force sensor will provide objective feedback to the students. Each student will be instructed on how to use the Active 5 device prior to utilization it in the classroom setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: learning spinal mobilization with a force sensor
Description: Experimental group will use a force sensor (Active5) while learning spinal mobilization during the practice lab portion of the class. The force sensor will provide objective feedback to the students. Each student will be instructed on how to use the Active 5 device prior to utilization it in the classroom setting.
Study: NCT04435262

Intervention type: OTHER
Intervention: Remote Monitoring
Description: Remote Monitoring Follow-up
Study: NCT02857907

Intervention type: OTHER
Intervention: Blood sample
Description: A blood sample is performed one year after kidney transplantation.

Intervention type: OTHER
Intervention: Blood sample
Description: A blood sample is performed one year after kidney transplantation.
Study: NCT04192448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Administration
Description: The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Administration
Description: The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Administration
Description: The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Alcohol Administration
Description: The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mood Induction
Description: The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mood Induction
Description: The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.
Study: NCT02796651

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for formoterol fumarate
Description: Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (12 μg)
Description: Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
Study: NCT04192448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mood Induction
Description: The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mood Induction
Description: The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.
Study: NCT00911547

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo tablet taken once daily at bedtime for 16 weeks
Study: NCT02380352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
Study: NCT05128435

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood sample taken 3 to 5 months after the infection
Study: NCT02155296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restorative Practices Intervention
Description: RPI has the 3 core components of an optimal comprehensive positive youth development intervention:~(1) sustained relationships with adults-RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building-RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building-As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restorative Practices Intervention
Description: RPI has the 3 core components of an optimal comprehensive positive youth development intervention:~(1) sustained relationships with adults-RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building-RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building-As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension.
Study: NCT04552535

Intervention type: DRUG
Intervention: Second line (2L) afatinib
Description: Afatinib

Intervention type: DRUG
Intervention: Second line chemotherapy
Description: Chemotherapy
Study: NCT02193269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill
Description: you will receive 0.0 mg as a single daily dose for 4 days
Study: NCT01803646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-101
Description: AM-101 gel for intratympanic injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel for intratympanic injection
Study: NCT03244605

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation Education
Description: General health education
Study: NCT01374841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
Study: NCT03244605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
Study: NCT01020838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben (BAY94-9172)
Description: Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
Study: NCT02470936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
Study: NCT02175212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short term androgen deprivation
Description: * Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long term androgen deprivation
Description: * Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short term androgen deprivation
Description: Minimum dose of 76 Gy (range 76-82 Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long term androgen deprivation
Description: Minimum dose of 76 Gy (range 76-82 Gy)
Study: NCT03244605

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
Study: NCT01290237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin hydrocloride
Description: see description of study arms
Study: NCT04118699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin oral tablet
Description: Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered investigational product (rifaximin) for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered placebo for 4 weeks
Study: NCT01221142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cincinnati Sub-Zero, Blanketrol III
Study: NCT00722215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123 (selective endothelin A receptor antagonist)
Description: Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % saline
Description: Single 15ml 0.9% saline infused for 15 mins as placebo control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Single dose of nifedipine 10 mg given orally as active control
Study: NCT05060679

Intervention type: OTHER
Intervention: Supportive therapy at the ICU
Description: Non-septic ICU patients received adequate supportive treatment (fluid resuscitation, respiratory, anticoagulation, antimicrobial and vasopressor therapy along with sedation, ulcer prophylaxis and nutrition. Blood sampling for non-septic patients were the first (T1) and third (T3) postoperative morning at the ICU. Besides, 23 healthy outpatients were documented without sepsis or sepsis-related organ dysfuntion as a control group.

Intervention type: OTHER
Intervention: Sepsis therapy
Description: Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis and nutrition. Blood samples were collected at the ICU from this patient group at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.

Intervention type: OTHER
Intervention: Sepsis-related organ dysfunction therapy
Description: Patient management of sepsis and sepsis-related organ dysfunction followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis, nutrition and renal replacement therapy (if needed). In this patient group, blood sampling was performed at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
Study: NCT03973424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple
Description: Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, use a simplified form of tracking only high-calorie, high-fat foods in the study smartphone app, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, track calorie intake, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
Study: NCT01290237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin hydrocloride
Description: see description of study arms